Capricor Therapeutics (NASDAQ:CAPR) Director Sells $1,848,365.05 in Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Director Karimah Es Sabar sold 61,265 shares of the firm’s stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Karimah Es Sabar also recently made the following trade(s):

• On Thursday, April 2nd, Karimah Es Sabar sold 7,529 shares of Capricor Therapeutics stock. The shares were sold at an average price of $32.00, for a total value of $240,928.00.
• On Wednesday, April 1st, Karimah Es Sabar sold 53,735 shares of Capricor Therapeutics stock. The stock was sold at an average price of $31.03, for a total value of $1,667,397.05.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR opened at $32.11 on Friday. Capricor Therapeutics, Inc. has a 12-month low of $4.30 and a 12-month high of $40.37. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -14.21 and a beta of 0.48. The stock’s 50 day simple moving average is $27.38 and its 200 day simple moving average is $19.10.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). As a group, equities analysts forecast that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Capricor Therapeutics

Several institutional investors have recently bought and sold shares of CAPR. Creek Drive Management Group LLC bought a new position in Capricor Therapeutics in the 4th quarter valued at about $1,039,000. SB Capital Management Inc acquired a new stake in shares of Capricor Therapeutics in the 4th quarter worth approximately $11,544,000. Ikarian Capital LLC lifted its stake in shares of Capricor Therapeutics by 118.4% in the 4th quarter. Ikarian Capital LLC now owns 578,015 shares of the biotechnology company’s stock worth $16,682,000 after acquiring an additional 313,373 shares during the period. Virtus Investment Advisers LLC boosted its holdings in shares of Capricor Therapeutics by 25.2% in the fourth quarter. Virtus Investment Advisers LLC now owns 10,224 shares of the biotechnology company’s stock valued at $295,000 after acquiring an additional 2,061 shares in the last quarter. Finally, Susquehanna Portfolio Strategies LLC acquired a new position in shares of Capricor Therapeutics during the fourth quarter valued at approximately $384,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics News Roundup

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Several brokerages have raised targets or issued overweight/buy ratings (Cantor Fitzgerald $62, Piper Sandler $58, Maxim $50), supporting upside expectations versus the consensus.
• Neutral Sentiment: One director sale (7,529 shares at $32.00) was executed under a pre‑arranged Rule 10b5‑1 plan, which typically mutes the negative signal from insider selling but does not eliminate market concern. SEC Filing
• Neutral Sentiment: Institutional ownership is modest (~21.7%) with a few small new positions reported — indicates some institutional interest but not large-scale conviction yet. Institutional Holdings
• Negative Sentiment: CFO Anthony Bergmann sold 25,000 shares on March 31 at an average $30.13 (disclosed in an SEC Form 4), reducing his direct holding by ~75% — a sizable insider reduction that may worry investors about near-term outlook or personal liquidity needs. CFO Sale Filing
• Negative Sentiment: Director Karimah Es Sabar sold large blocks across March 31–April 1–2 (61,265 @ $30.17; 53,735 @ $31.03; plus a 7,529 @ $32.00 sale under a 10b5‑1 plan). Combined insider disposals this week total roughly 148k shares for several million dollars — a significant decrease in insider ownership that can pressure sentiment. Director Sale Filing
• Negative Sentiment: Capricor missed Q4 EPS estimates (reported -$0.62 vs. consensus -$0.51 on March 12), which is a near-term fundamental negative that analysts and investors will weigh against bullish price targets. Earnings Report

Analysts Set New Price Targets

A number of analysts recently weighed in on CAPR shares. Piper Sandler reaffirmed an “overweight” rating and issued a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. UBS Group set a $50.00 target price on shares of Capricor Therapeutics in a research report on Monday, December 15th. Oppenheimer raised their price target on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. B. Riley Financial lifted their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a report on Friday, March 13th. Finally, Wall Street Zen downgraded Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $46.09.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.